发明名称 |
Diagnostic method for determining whether to discontinue pegylated uricase therapy |
摘要 |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions. |
申请公布号 |
IL216956(A) |
申请公布日期 |
2016.10.31 |
申请号 |
IL20110216956 |
申请日期 |
2011.12.13 |
申请人 |
CREALTA PHARMACEUTICALS LLC;SAVIENT PHARMACEUTICALS INC. |
发明人 |
|
分类号 |
G01N |
主分类号 |
G01N |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|